{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:24:01Z","timestamp":1791901441815,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,4,15]],"date-time":"2012-04-15T00:00:00Z","timestamp":1334448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00417-012-2008-6","type":"journal-article","created":{"date-parts":[[2012,4,14]],"date-time":"2012-04-14T03:22:52Z","timestamp":1334373772000},"page":"1161-1167","source":"Crossref","is-referenced-by-count":8,"title":["The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis"],"prefix":"10.1007","volume":"250","author":[{"given":"Selcuk","family":"Tunik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Nergiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Keklikci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Akkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,15]]},"reference":[{"key":"2008_CR1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1167\/iovs.03-0940","volume":"45","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW (2004) Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 45:1117\u20131124","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2008_CR2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.ico.0000183485.85636.ff","volume":"25","author":"C Cursiefen","year":"2006","unstructured":"Cursiefen C, Maruyama K, Jackson DG, Streilein JW, Kruse FE (2006) Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25:443\u2013447","journal-title":"Cornea"},{"key":"2008_CR3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajo.2006.03.058","volume":"142","author":"SJ Bakri","year":"2006","unstructured":"Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162\u2013164","journal-title":"Am J Ophthalmol"},{"key":"2008_CR4","doi-asserted-by":"crossref","first-page":"51985","DOI":"10.1074\/jbc.C300454200","volume":"278","author":"Y Yamazaki","year":"2003","unstructured":"Yamazaki Y, Takani K, Atoda H, Morita T (2003) Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor-2). J Biol Chem 278:51985\u201351988","journal-title":"J Biol Chem"},{"key":"2008_CR5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242\u2013248","journal-title":"Nature"},{"key":"2008_CR6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","volume":"104","author":"F Bock","year":"2007","unstructured":"Bock F, K\u00f6nig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336\u2013344","journal-title":"Ophthalmologe"},{"key":"2008_CR7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/er.18.1.4","volume":"18","author":"N Ferrara","year":"1997","unstructured":"Ferrara N, Davis Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4\u201325","journal-title":"Endocr Rev"},{"key":"2008_CR8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035\u20131047","journal-title":"Ophthalmology"},{"key":"2008_CR9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"issue":"23","key":"2008_CR10","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"issue":"17","key":"2008_CR11","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2165\/00003495-200767170-00008","volume":"67","author":"SK Blick","year":"2007","unstructured":"Blick SK, Scott LJ (2007) Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 67(17):2585\u20132607","journal-title":"Drugs"},{"issue":"4","key":"2008_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","volume":"7","author":"S Li","year":"2005","unstructured":"Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4):301\u2013311","journal-title":"Cancer Cell"},{"key":"2008_CR13","first-page":"45","volume-title":"Animal anaesthesia","author":"CJ Green","year":"1982","unstructured":"Green CJ (1982) Animal anaesthesia. Laboratory Animals Ltd., London, pp 45\u201358"},{"issue":"5","key":"2008_CR14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","volume":"4","author":"J Mahoney","year":"1985","unstructured":"Mahoney J, Waterbury LD (1985) Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 4(5):531\u2013535","journal-title":"Curr Eye Res"},{"key":"2008_CR15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","volume":"438","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932\u2013936","journal-title":"Nature"},{"key":"2008_CR16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm0603-653","volume":"9","author":"P Carmeliet","year":"2003","unstructured":"Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653\u2013660","journal-title":"Nat Med"},{"key":"2008_CR17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967\u2013974","journal-title":"Nature"},{"key":"2008_CR18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/labinvest.3700526","volume":"87","author":"F Shojaei","year":"2007","unstructured":"Shojaei F, Ferrara N (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 87:227\u2013320","journal-title":"Lab Invest"},{"key":"2008_CR19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","volume":"41","author":"SS Lyn","year":"2007","unstructured":"Lyn SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614\u2013625","journal-title":"Ann Pharmacother"},{"key":"2008_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1167\/iovs.01-1277","volume":"44","author":"AM Joussen","year":"2003","unstructured":"Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis AP (2003) VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 44:117\u2013123","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"2008_CR21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMp048143","volume":"351","author":"D Schrag","year":"2004","unstructured":"Schrag D (2004) The price tag on progress\u2013chemotherapy for colorectal cancer. N Engl J Med 351(4):317\u2013319","journal-title":"N Engl J Med"},{"issue":"10","key":"2008_CR22","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","volume":"245","author":"M Erdurmus","year":"2007","unstructured":"Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245(10):1577\u20139","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2008_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363\u2013372","journal-title":"Ophthalmology"},{"key":"2008_CR24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab(Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278","journal-title":"Retina"},{"key":"2008_CR25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","volume":"91","author":"RP Manzano","year":"2007","unstructured":"Manzano RP, Peyman GA, Khan P, Carvounis P, Kivilcim M (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). BrJ Ophthalmol 91:804\u2013807","journal-title":"BrJ Ophthalmol"},{"key":"2008_CR26","first-page":"2326","volume":"15","author":"O Dratviman-Storobinsky","year":"2009","unstructured":"Dratviman-Storobinsky O, Lubin BC, Hasanreisoglu M, Goldenberg-Cohen N (2009) Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol Vis 15:2326\u20132338","journal-title":"Mol Vis"},{"key":"2008_CR27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00005072-199605000-00004","volume":"55","author":"T Bohling","year":"1996","unstructured":"Bohling T, Hatva E, Kujala M, Claesson-Welsh L, Alitalo K, Haltia M (1996) Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol 55:522\u20137","journal-title":"J Neuropathol Exp Neurol"},{"key":"2008_CR28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1091\/mbc.4.1.121","volume":"4","author":"CK Goldman","year":"1993","unstructured":"Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121\u201333","journal-title":"Mol Biol Cell"},{"key":"2008_CR29","first-page":"2926","volume":"60","author":"CJ Bruns","year":"2000","unstructured":"Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926\u20132935","journal-title":"Cancer Res"},{"key":"2008_CR30","first-page":"747","volume":"6","author":"J Mendelsohn","year":"2000","unstructured":"Mendelsohn J (2000) Blockade of receptors for growth factors: an anticancer therapy the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award lecture. Clin Cancer Res 6:747\u2013753","journal-title":"Clin Cancer Res"},{"key":"2008_CR31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/BF03401737","volume":"4","author":"RS Kerbel","year":"1998","unstructured":"Kerbel RS, Viloria-Petit A, Okada F, Rak J (1998) Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4:286\u2013295","journal-title":"Mol Med"},{"key":"2008_CR32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ajo.2008.09.022","volume":"147","author":"M Guler","year":"2009","unstructured":"Guler M, Yilmaz T, Ozercan I, Elkiran T (2009) The \u0131nhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 147:703\u2013708","journal-title":"Am J Ophthalmol"},{"key":"2008_CR33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/363083a0","volume":"363","author":"M Rozakis-Adcock","year":"1993","unstructured":"Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D (1993) The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature (Lond) 363:83\u201385","journal-title":"Nature (Lond.)"},{"key":"2008_CR34","first-page":"1279","volume":"141","author":"RM Strieter","year":"1992","unstructured":"Strieter RM, Kunkel SL, Elner VM, Martonyi CL, Koch AE, Polverini PJ, Elner SG (1992) Interleukin-8.A corneal factor that induces neovascularization. Am J Pathol 141:1279\u20131284","journal-title":"Am J Pathol"},{"issue":"4","key":"2008_CR35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1442-9071.2010.02252.x","volume":"38","author":"L Hoffart","year":"2010","unstructured":"Hoffart L, Matonti F, Conrath J, Daniel L, Ridings B, Masson GS, Chavane F (2010) Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone. Clin Exp Ophthalmol 38(4):346\u2013352","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-012-2008-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-012-2008-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-012-2008-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T08:59:44Z","timestamp":1561625984000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-012-2008-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,15]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["2008"],"URL":"https:\/\/doi.org\/10.1007\/s00417-012-2008-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,15]]}}}